Jefferies analyst Tycho Peterson initiated coverage of Caris Life Sciences (CAI) with a Buy rating and $28 price target The firm sees “secular tailwinds” in the oncology diagnostics space from improving therapies and declining sequencing costs, but also “ongoing polarization between the leaders and laggards.” Jefferies views Caris Life Sciences and Veracyte as “compelling stocks” given their profitability, pipelines and valuations.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAI:
- Caris Life Sciences initiated with a Neutral at Piper Sandler
- Caris Life Sciences price target lowered to $30 from $34 at Evercore ISI
- Caris Life Sciences launches Caris ChromoSeq tumor profiling assay
- Caris Life Sciences initiated with a Buy at Goldman Sachs
- Caris Life Sciences announces finalized Achieve 1 Study results